comprehensive -WSS

comprehensive

author：explore 2025-10-03 00:37:59 - browse：8691

Silver Apple Watch — Charles Rex Arbogast/AP

Rune Labs, maker of an Apple Watch app that can track symptoms related to Parkinson’s disease, announced Thursday $12 million in funding led by Nexus NeuroTech, a new venture capital fund focused on brain disorders.

Rune in 2022 received Food and Drug Administration clearance for StrivePD, an Apple Watch app that uses the device’s sensors to track two Parkinson’s-related symptoms: tremors and dyskinesia, or the involuntary movements that are a side effect of medication. The app also collects sleep, activity, and medication data and can serve as a focal point for education and care management for people with Parkinson’s. The app can help users make day-to-day decisions about lifestyle and medication and help inform care decisions by providers. Rune also works with drug companies developing treatments for the disease.

Rune Labs CEO Brian Pepin told STAT the company will use the funds to push the adoption of its technology among health plans that can use it to manage care for their members with Parkinson’s disease. The company last year finalized a deal with “a large California health system” and now hopes to go out and sell to more organizations that have Medicare Advantage plans or other at-risk populations they serve. This requires an investment in business development staff and people to manage those relationships.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： FTC loses bid to block Novant's North Carolina hospital merger

leisure time

WSS

Why Titanic fascinates society, still drawing tours to the wreckage

House panel to mark up pandemic

Take antibiotics after sex, CDC recommends for certain risk groups

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA approves Moderna’s RSV vaccine, its second licensed product

explore

comprehensive

explore

The cancer drug shortage isn’t new — and neither are the solutions

Rare Northern Lights show in US this week: Where and how to see it

How to save PrEP access — and even expand it

Congress needs to close a vaccine

Walensky prepares to leave CDC — and Congress — behind

The PBM ad wars are taking over Washington, D.C.

Duchenne breakthrough therapy leaves behind pioneering families

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Malaria cases in Florida and Texas: Here’s what you need to know

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

CMS got Medicare Advantage quality rating wrong, judge rules

Data don't support strong claims for Covid

With fresh data, a dynamic duo powers Eli Lilly to new heights

Structure Therapeutics oral GLP

BD to buy Edwards patient monitoring unit for $4.2 billion

focus

hotspot

leisure time

Wikipedia